The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
17 May, 2022
While COPD exacerbations are largely responsible for the morbidity and mortality of COPD, their management is suboptimal and remains unchanged for decades. One of the main reasons is that the design and conduct of clinical trials to test new treatments is very challenging. Selection of outcomes (endpoints) represent one of the challenges clinical researchers face.
More specifically, clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or important to patients. An ERS Task Force was formed and developed a core outcome set, a consensus-based minimum set of important outcomes that are recommended to be evaluated in all future clinical trials on the management of COPD exacerbations, to improve their clinical value, quality, and comparability. This core outcome set was informed by global, multi-stakeholder consensus.
The selected outcomes reflect the main treatment objectives for COPD exacerbations. Beyond clinical trials, it is also important that these are also assessed in observational studies and to be considered in clinical practice.
During this session, we will describe the challenges that researchers face when conducting clinical trials of COPD exacerbations management. We will focus on the importance of core outcome sets and will describe the ERS COPD exacerbations core outcome set and how it was developed.
Following this webinar, participants will be able to: